BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25804379)

  • 41. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
    García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
    Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
    Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
    Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aggressive variants of follicular cell-derived thyroid carcinomas: a cytopathologist's perspective.
    Lastra RR; LiVolsi VA; Baloch ZW
    Cancer Cytopathol; 2014 Jul; 122(7):484-503. PubMed ID: 24664970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.
    Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P
    Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
    Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
    Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas.
    Pallante P; Visone R; Croce CM; Fusco A
    Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
    Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
    J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed?
    Dettmer M; Schmitt A; Steinert H; Haldemann A; Meili A; Moch H; Komminoth P; Perren A
    Am J Surg Pathol; 2011 Dec; 35(12):1866-72. PubMed ID: 21989341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significance of what is not sampled: Characteristics of thyroid nonmicrocarcinomas (>1.0 cm) that were not targeted.
    Schoedel KE; Wolfe J; Hodak SP; Lebeau SO; Yip L; Carty SE; Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2015 Nov; 123(11):678-83. PubMed ID: 26242638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
    Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
    Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer.
    Liska J; Altanerova V; Galbavy S; Stvrtina S; Brtko J
    Endocr Regul; 2005 Sep; 39(3):73-83. PubMed ID: 16468229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
    Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mitochondrial DNA alterations in thyroid cancer.
    Tong BC; Ha PK; Dhir K; Xing M; Westra WH; Sidransky D; Califano JA
    J Surg Oncol; 2003 Mar; 82(3):170-3. PubMed ID: 12619060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.
    Uchino S; Noguchi S; Kawamoto H; Yamashita H; Watanabe S; Yamashita H; Shuto S
    World J Surg; 2002 Aug; 26(8):897-902. PubMed ID: 11965446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mixed squamous cell carcinoma and follicular carcinoma of the thyroid gland.
    Mercante G; Marchesi A; Covello R; Dainese L; Spriano G
    Auris Nasus Larynx; 2012 Jun; 39(3):310-3. PubMed ID: 21855238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma.
    Zafon C; Obiols G; Castellví J; Tallada N; Galofré P; Gemar E; Mesa J; Simó R
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3975-80. PubMed ID: 11502841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.